Xpert bladder cancer monitor in surveillance of bladder cancer : Systematic review and meta-analysis
Copyright © 2021 Elsevier Inc. All rights reserved..
INTRODUCTION: There is a need for sensitive and specific biomarkers for detecting recurrences in patients with non-muscle invasive bladder cancer (NMIBC) on surveillance. Xpert bladder cancer (BC) monitor is the latest rapid in vitro qualitative test that detects expression of 5 mRNAs using a GeneXpert instrument. The primary aim of this review was to systematically review and pool the data regarding the diagnostic performance of Xpert BC in patients with NMIBC.
METHODS: Systematic literature search using 4 electronic databases (PubMed, EMbase, Scopus and Web of science) was performed. Pooled sensitivity, specificity and diagnostic odds ratio (DOR) were estimated using DerSimonian-Laird random-effects model. Standard Preferred Reporting Items for Systematic reviews and Meta-analysis guidelines were followed and the study protocol was registered with PROSPERO (CRD42021249762).
RESULTS: In this review, 11 prospective studies with 2,896 patients were included. Pooled sensitivity and specificity for Xpert BC were 73% (95% confidence interval (CI) 65%-80%) and 77% (95% CI 69%-84%) respectively. Area under curve (AUC) for Xpert BC monitor was 0.81 (0.78-0.84) respectively. Subgroup analysis from 7 studies for patients with high-grade recurrence revealed sensitivity, specificity and AUC of 0.86 (0.77-0.92), 0.78 (0.75-0.81) and 0.87 (0.84-0.90) respectively. Similar analysis for patients with low-grade recurrence revealed sensitivity, specificity and AUC of 0.58 (0.47-0.68), 0.79 (0.75-0.82) and 0.79 (0.75-0.82) respectively.
CONCLUSION: Xpert BC monitor has overall acceptable diagnostic accuracy. Sensitivity is higher for high-grade disease for detecting recurrences in patients with NMIBC on surveillance.
| Errataetall: |
CommentIn: Urol Oncol. 2022 Feb;40(2):68-69. - PMID 34848123 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Urologic oncology - 40(2022), 4 vom: 14. Apr., Seite 163.e1-163.e9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sharma, Gopal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 20.04.2022 Date Revised 20.04.2022 published: Print-Electronic CommentIn: Urol Oncol. 2022 Feb;40(2):68-69. - PMID 34848123 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.urolonc.2021.08.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330773097 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330773097 | ||
| 003 | DE-627 | ||
| 005 | 20231225212014.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.urolonc.2021.08.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1102.xml |
| 035 | |a (DE-627)NLM330773097 | ||
| 035 | |a (NLM)34535354 | ||
| 035 | |a (PII)S1078-1439(21)00380-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sharma, Gopal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Xpert bladder cancer monitor in surveillance of bladder cancer |b Systematic review and meta-analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.04.2022 | ||
| 500 | |a Date Revised 20.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Urol Oncol. 2022 Feb;40(2):68-69. - PMID 34848123 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
| 520 | |a INTRODUCTION: There is a need for sensitive and specific biomarkers for detecting recurrences in patients with non-muscle invasive bladder cancer (NMIBC) on surveillance. Xpert bladder cancer (BC) monitor is the latest rapid in vitro qualitative test that detects expression of 5 mRNAs using a GeneXpert instrument. The primary aim of this review was to systematically review and pool the data regarding the diagnostic performance of Xpert BC in patients with NMIBC | ||
| 520 | |a METHODS: Systematic literature search using 4 electronic databases (PubMed, EMbase, Scopus and Web of science) was performed. Pooled sensitivity, specificity and diagnostic odds ratio (DOR) were estimated using DerSimonian-Laird random-effects model. Standard Preferred Reporting Items for Systematic reviews and Meta-analysis guidelines were followed and the study protocol was registered with PROSPERO (CRD42021249762) | ||
| 520 | |a RESULTS: In this review, 11 prospective studies with 2,896 patients were included. Pooled sensitivity and specificity for Xpert BC were 73% (95% confidence interval (CI) 65%-80%) and 77% (95% CI 69%-84%) respectively. Area under curve (AUC) for Xpert BC monitor was 0.81 (0.78-0.84) respectively. Subgroup analysis from 7 studies for patients with high-grade recurrence revealed sensitivity, specificity and AUC of 0.86 (0.77-0.92), 0.78 (0.75-0.81) and 0.87 (0.84-0.90) respectively. Similar analysis for patients with low-grade recurrence revealed sensitivity, specificity and AUC of 0.58 (0.47-0.68), 0.79 (0.75-0.82) and 0.79 (0.75-0.82) respectively | ||
| 520 | |a CONCLUSION: Xpert BC monitor has overall acceptable diagnostic accuracy. Sensitivity is higher for high-grade disease for detecting recurrences in patients with NMIBC on surveillance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Bladder cancer | |
| 650 | 4 | |a Diagnostic accuracy | |
| 650 | 4 | |a Systematic review | |
| 650 | 4 | |a Xpert | |
| 700 | 1 | |a Sharma, Abhay |e verfasserin |4 aut | |
| 700 | 1 | |a Krishna, Murali |e verfasserin |4 aut | |
| 700 | 1 | |a Devana, Sudheer Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Shrawan Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Urologic oncology |d 1995 |g 40(2022), 4 vom: 14. Apr., Seite 163.e1-163.e9 |w (DE-627)NLM097435058 |x 1873-2496 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:4 |g day:14 |g month:04 |g pages:163.e1-163.e9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.urolonc.2021.08.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 4 |b 14 |c 04 |h 163.e1-163.e9 | ||